India's benchmark Nifty 50 index is set to open marginally higher on Thursday after sinking into correction territory in the ...

Mumbai: Cipla has announced that the United States Food and Drugs Administration (USFDA) has concluded an inspection at the ...

Stay informed with the Cipla Stock Liveblog, your comprehensive resource for real-time updates and in-depth analysis of a ...

Cipla’s FDA-compliant facilities and its investments in US-based units place it in a strong position to weather potential ...

NSE's Nifty50 tumbled 324.40 points, or 1.36 per cent, to close at 23,559.05 for the day. Some buzzing pharma stocks ...

Shivam Puri, CEO, Cipla Health, discusses the brand proposition of Prolyte ORS, shares strategy that helped brand achieve Rs ...

Following an inspection of its Bengaluru facility, Cipla has received 8 observations in Form 483 from the US Food and Drug ...

Cipla , India's third-largest generic drugmaker by sales, reported a 15.2% rise in second-quarter profit that beat estimates, ...

Here's the complete list of investment and trading ideas for the day. Buy Garden Reach shares in the cash segment for a ...

Indian shares fell on Wednesday, dragged down by high weightage financials and as drugmaker Cipla extended its post-results losses.

The US Food and Drugs Administration (USFDA) conducted an inspection at the company's manufacturing facility in Virgonagar, ...

(Reuters) -Cipla, India's third-largest generic drugmaker by sales, reported a 15.2% rise in second-quarter profit that beat estimates, driven by higher sales of its respiratory and cancer drugs ...